Thrombin-mediated endothelial cell release of von Willebrand Factor (VWF) and Pselectin functionally links Protease-Activated Receptors (PARs) to thrombosis and inflammation. VWF release can be stimulated by both Ca 2+ and cAMP, and although both VWF and P-selectin are found in Weibel-Palade bodies (WPBs), we found that their release could be differentially regulated. In these studies, human umbilical vein endothelial cells stimulated with cAMP or PAR2-AP led to a delayed release of VWF and significantly less P-selectin release compared to histamine, thrombin or PAR1-AP.
Introduction
Thrombin is the major protease in the coagulation cascade whose pleiotropic actions can ultimately lead to thrombosis and tissue injury. Thrombin displays a diverse range of effects in vascular cells that functionally connects tissue damage to both hemostatic and inflammatory responses 1 ,2 . Thrombin stimulation of the release of preformed von Willebrand factor (VWF) and P-selectin from endothelial cells links inflammation and atherosclerosis, as VWF facilitates platelet aggregation at sites of vascular injury 3 and P-selectin is involved in adhesion of leukocytes to endothelial cells 4 . Elevated levels of VWF predict adverse outcomes in acute coronary syndromes and may be a biochemical surrogate for endothelial cell dysfunction 5, 6 . P-selectin is a transmembrane protein of the selectin family and plays a critical role early in the inflammatory response by mediating the rolling of leukocytes on the endothelium. It has been suggested that P-selectin may be involved in atherosclerosis since P-selectin deficiency delays and reduces atherosclerotic lesion formation 7, 8 . Much interest has also been given to soluble P-Selectin since this was first proposed to be a marker of platelet activation in 1997 9 . Recent evidence suggests that soluble P-selectin may play a key role in hemostasis and thrombosis 10,11 ,12 . The source of soluble P-selectin has been debated since P-selectin is found in both platelets and Weibel-Palade bodies.
Most investigators believe the major source of soluble P-selectin is platelets 13 .
Many of the cellular effects of thrombin are initiated via activation of a family of protease-activated receptors (PARs), which are coupled to heterotrimeric G proteins.
PARs are unique among G protein-Coupled Receptors (GPCRs) in that they are activated by thrombin through proteolytic generation of a tethered ligand. Thus far, four
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From PARs have been cloned and characterized (PAR1-PAR4). HUVEC express both PAR1 and PAR2, while PAR3 transcripts have been found at considerably lower levels when compared to PAR1 14 . Thrombin stimulates PAR1 and PAR3, while trypsin/tryptase and coagulation proteases upstream of thrombin (e.g. tissue factor/VIIa complex, factor Xa and the cognate ternary complex) stimulate PAR2 15 . PAR2 plays a pivotal, yet undefined role, in inflammation and ischemia with evidence for both pro and antiinflammatory roles 15 . Many of the studies on thrombin activation of biochemical and functional effects in endothelial cells were done before it was known that multiple PARs existed. Additionally, the agonist peptide used for activation of PAR1, which is referred to as thrombin receptor activating peptide (TRAP, SFLLRNDKYEPF), can also activate PAR2 on endothelial cells 16, 17 . For example, thrombin and TRAP have been shown to mediate leukocyte rolling in rat mesenteric venules via P-selectin and sialyl Lewis X 18 .
These effects could be mediated by either PAR1 or PAR2 given that TRAP can activate PAR2. However, substitution of the serine to threonine yields a PAR1 specific peptide (TFLLRNPND) 19 .
Endothelial cells contain elongated endothelial storage vesicles called WeibelPalade bodies (WPB) that are involved in the regulated secretion of mature VWF and P-selectin 20, 21 . VWF and P-selectin are the best characterized constituents of WPBs, and several lines of evidence exist for their close association. VWF knockout mice also display defective leukocyte attachment implicating a lack of P-selectin expression 22 .
More recently P-selectin has been shown to mediate the attachment of ultra large VWF multimers to the endothelial surface upon release 23 .
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Cell Culture
HUVEC were isolated 28 and cultured in medium 199 supplemented with 15% FBS, endothelial mitogen, penicillin, streptomycin, amphotericin B, and heparin. Primary HUVEC were plated out in gelatin coated 48 well plates and assayed 2 days after becoming confluent. Cells were washed once with M199/0.1% BSA and were stimulated with indicated agonists and the conditioned media was collected at 15 minutes and assayed for VWF activity, while cells were assayed for P-selectin. All experiments were conducted in Passage 1 HUVEC except where otherwise noted.
Cell based P-selectin assay
HUVEC were stimulated with indicated agents and then fixed for 5 minutes with 0.5% paraformaldehyde solution and washed and blocked. Mouse anti-P-selectin antibodies (Research & Diagnostics, Inc.) were then added and incubated @ RT for 1 hour, washed and blocked. Goat anti-mouse HRP-conjugated 2 o -antibody (KRL) was then added for 1 hour followed by washing and then analyzed at 450nM after addition of substrate. Soluble P-selectin was measured using the soluble P-selectin kit from R&D systems.
Von Willebrand Factor Assay
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Samples were analyzed using a sandwich ELISA for VWF utilizing a polyclonal rabbit anti-VWF antibody (DAKO) in combination with HRP-conjugated anti-VWF antibody (DAKO) according to the manufacturer's protocol. A standard curve for VWF was generated from serial dilutions of normal human serum with extrapolation of levels using a standard amount of purified VWF. 
Intracellular

Subcloning of soluble P-selectin
Total RNA was isolated from HUVEC cells with the total RNA isolation kit (Aurum 
9
CTA GGT GGC TGT GAG GAT TC-3'. The PCR products were analyzed by agarose gel electrophoresis and sequenced.
Construction of P-selectin and soluble-P-selectin vectors
Total RNA was isolated from HUVEC cells with the total RNA isolation kit (Aurum TM Total RNA Mini Kit) from BIO-RAD, and RT-PCR was carried out using the ThermoScript TM RT-PCR system from Invitrogen. PCR was performed using two primers containing BspE 1 and Sal 1 restriction sites. The primers used were as follows:
Forward primer: 5'-ATA TCC GGA AGC AGA GTC ACA GAG GAG ATG GC-3';
Reverse primer: 5'-AAT GTC GAC GGT CCA GAG CGG GTC CAA CAG-3'. Full-length cDNAs encoding human P-selectin were subcloned into the pECFP-C1 vector at the For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
Results
The effects of thrombin, PAR-APs, forskolin, and histamine on release of Pselectin and von Willebrand Factor.
To examine the effects of agonist-mediated release of WPB contents in HUVEC, we conducted time course experiments in which we measured VWF in the media while measuring cell surface expression of P-selectin. Thrombin and PAR1-AP (TFLLRNPND)-mediated release of VWF is maximal at approximately 15 minutes, while PAR2-AP (SLIGKV) -mediated release of P-selectin is delayed compared to PAR1-AP or thrombin ( Figure 1A ) and more closely resembles Forskolin-mediated release of VWF ( Figure 1B ). Maximal release of P-selectin occurs more rapidly, with maximal levels seen at approximately 5 minutes for all agonists tested ( Figures 1C and D) . The magnitude of PAR2-AP-mediated P-selectin release was less than PAR1-AP, thrombin, or histamine, while forskolin-mediated release of P-selectin was even less compared to PAR2-AP, and isoproterenol had no effect.
To examine how the differences in the time courses in Figure 1 seen with PAR1-AP and PAR2-AP translated into differences in efficacy, we conducted dose response studies. Addition of histamine produced nearly identical responses for both VWF release and P-selectin cell-surface expression ( Figure 2A ). Dose response studies with thrombin yielded similar EC 50 s for release of VWF and cell surface expression of Pselectin, however, the magnitude of response or efficacy was statistically significantly greater for P-selectin cell-surface expression than for VWF release ( Figure 2B ).
Application of PAR1-AP was slightly more efficacious for cell-surface P-selectin expression compared to release of VWF, similar to thrombin ( Figure 2C ). However, addition of PAR2-AP resulted in an opposite pattern compared to PAR1-AP with a greater efficacy with VWF release compared to P-selectin ( Figure 2D ). Importantly, HUVEC express only the Histamine 1 (H1) receptor subtype as determined pharmacologically 29 , which reportedly couples only to G q 30 . This suggests that PARs, which couple to more G proteins than the histamine receptor, may mediate the release of VWF and P-selectin through multiple G proteins/pathways.
The Role of Ca 2+ Mobilization in VWF and P-selectin Release in HUVEC.
Since the secretion of VWF occurs after intracellular Ca 2+ levels rise 24 , and peak elevations in cytoplasmic free Ca 2+ correlate with VWF secretion in HUVEC 31 , we next examined the ability of the same agonists to mobilize intracellular Ca 2+ . The peak level of Ca 2+ mobilization in response to histamine or PAR2-AP was nearly identical and resulted in nearly a 3 fold increase in intracellular Ca 2+ in HUVEC ( Figure 3A and B).
When dose response curves were generated for histamine and PAR2-AP-mediated mobilization of Ca 2+ and overlaid with the dose response curves for both VWF and Pselectin release (Figure 2 ), the PAR2-AP Ca 2+ dose response curve is significantly shifted to the left compared to both VWF and P-selectin. This suggests that PAR2-mediated VWF and P-selectin release requires additional pathways in addition to intracellular Ca 2+ mobilization. In contrast, the histamine dose response curve ( Figure   3C ) suggests that Ca 2+ mobilization is sufficient to mediate both VWF and P-selectin release. Intriguingly, the thrombin dose response curve for Ca 2+ mobilization overlays with both P-selectin and VWF release ( Figure 4C ), while the dose response curve for PAR1-AP-mediated Ca 2+ mobilization is shifted to the left when compared to both VWF and P-selectin release ( Figure 4D ). This could reflect that peptide activation when Figure 3E ). Pre-incubation with BAPTA-AM significantly inhibited the effect of PAR1-AP and thrombin on VWF release (85% and 75% respectively), while it had only a modest effect on thrombin and PAR1-AP mediated cellsurface P-selectin expression (50% and 28% respectively, Figure 3F ). Ca 2+ chelation inhibited PAR2-AP stimulation of both VWF and P-selectin release by 39% and 34%, respectively when compared to control. This data is consistent with the hypothesis that PAR2 activation stimulates additional pathways that regulate the release of both VWF and P-selectin.
Regulated secretion of soluble P-selectin by PARs in HUVEC.
One alternative explanation for the disparate release of VWF and P-selectin caused by PAR1-AP and PAR2-AP is that activation of PAR2 might lead to the preferential release of soluble P-selectin. To address this issue, soluble P-selectin was
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Stimulation of HUVEC with either thrombin or PAR1-AP or PAR2-AP resulted in a significant increase in soluble P-selectin when compared to control. However, no significant difference was observed when comparing the different agonists ( Figure 5A ).
This suggests that the relatively poor ability of PAR2-AP to stimulate cell-surface expression of P-selectin when compared to PAR1-AP is not secondary to the preferential release of soluble P-selectin by PAR2-AP.
The source of soluble P-selectin is controversial, and thought to be either derived from proteolytic removal or shedding of P-selectin from cell-surface P-selectin or derived from alternatively spliced P-selectin that lacks the transmembrane domain 34, 35 .
To address the source of soluble p-selectin in our population of HUVEC, we first cloned the alternatively spliced isoform of P-selectin from HUVEC total RNA. PCR primers were then designed to amplify the region encoding the trasmbembrane domain so that the 120 base pair difference in size between the full-length and the alternatively spliced different HUVEC preparations of total RNA yielded two major bands that corresponded with the full length and the alternatively spliced isoform of P-selectin. The full length isoform predominated and based on our semi-quantitative analysis appears to be present in a 3 -5 fold excess when compared to the alternatively spliced isoform ( Figure   5B ).
Because of the ongoing synthesis of VWF evident by the peri-nuclear staining in HUVEC ( Figure 7 ) and the delayed PAR2-AP-mediated release of VWF ( Figure 1A ), we needed to exclude the possibility that activation of PAR2 leads to increased synthesis of VWF and subsequent release of VWF via the constitutive pathway. Inhibition of protein
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The role of cAMP in PAR-mediated release of VWF and P-selectin.
PAR2-AP induced a delayed release of VWF and modest cell-surface expression of P-selectin compared to PAR1-AP. This more closely resembled the pattern of forskolin. As PAR2 has been reported to increase cAMP in certain human cells lines 36 ,
one hypothesis for PAR2-AP's similarity to forskolin might be that PAR2 couples to the G s /adenylyl cyclase pathway to increase cAMP levels. To address this possibility, we measured agonist mediated rises in intracellular cAMP in HUVEC. Forskolin caused a 3-fold increase in cAMP levels, while isoproterenol caused approximately a 60-80% increase ( Figure 6A ), which correlated with the ability of forskolin to increase VWF levels to a greater extent than isoproterenol ( Figure 1B ). PAR2-AP failed to increase global intracellular cAMP ( Figure 6B ). Time course studies also showed that PAR2-AP did not cause an increase in global cAMP (data not shown). However, inhibition of Protein Kinase A with H-89 resulted in a 60% decrease in forskolin-mediated VWF release and a 43% decrease in PAR2-AP-mediated VWF release, while not statistically altering PAR1-AP mediated release of VWF ( Figure 6D ). Pretreatment with forskolin did not alter PAR1-AP mediated release of P-selectin, but did cause a small, but statistically significant decrease (17%) in PAR2-AP mediated release of P-selectin. However, H-89 did not alter PAR1 or PAR2-AP mediated release of P-selectin ( Figure 6D ). In addition, The differential responses in the release of VWF and cell-surface expression of P-selectin motivate the hypothesis that VWF and P-selectin are not stored in the same secretory granule (WPB). Differential pathways of VWF and t-PA release in HUVEC with respect to pertussis toxin sensitivity and levels of intracellular Ca 2+ have been described 37 . These functional differences may have a structural explanation, as it has been observed that t-PA is stored in small dense vesicles distinct from WPBs 38 .
However, this observation is controversial as other studies have shown that t-PA is stored in WPBs in HUVEC 39 ,40,41 . Indeed, some of the observed differences in localization of t-PA have been ascribed to subtle differences in tissue culture methods 39 . Accordingly, we examined the localization of VWF and P-selectin in our cell culture system by performing immunostaining and confocal microscopy. The majority of Pselectin is localized with VWF in the characteristic WPB in HUVEC; however, some granules appear to be composed of primarily P-selectin ( Figure 7 , see red line).
However, further analysis of the cross sections (Z-sections) reveals intimate colocalization at every level when examined more objectively with the histogram ( Figure   7 ). In contrast, some granules appear to be composed of primarily VWF ( Figure 7 and Figure 8A , see white arrows) and when examined objectively only stain for VWF (data not shown).
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One explanation for the ability of PAR2-AP and forskolin to cause selective release of VWF and only minimal release of P-selectin, is that activation of PAR2 and increases in intracellular cAMP cause the selective release of WPB that contain predominately VWF. To test this hypothesis, HUVEC were stimulated with thrombin, PAR1-AP, PAR2-AP, histamine, or forskolin and then immunostained for VWF and Pselectin ( Figure 8A ) and the number of WPB was then quantified ( Figure 8B ). Through the use of confocal image analysis software (MetaMorph) it was determined that nearly all of the WPB that stained positive for P-selectin, also had underlying VWF, which correlated with the above data in Figure 7 . In contrast, there exists a population of WPB that contain only VWF. Therefore, WPB counted as green were characterized as containing both P-selectin and VWF, while those staining red for VWF were characterized as containing VWF. As demonstrated in Figure 8 , the response to PAR2-AP is similar to forskolin as there are less WPB containing VWF than control.
Application of forskolin resulted in virtually no change in the population of WPB that contain both P-selectin and VWF. Stimulation with PAR2-AP resulted in a small decrease in WPB containing both P-selectin and VWF, which more resembled the response of forskolin than PAR-1. In contrast, stimulation with PAR1-AP or histamine depletes both populations of WPB which correlates with the above pharmacological data.
Discussion
Our studies have demonstrated differential effects on secretion of VWF and Pselectin. This suggests that VWF and P-selectin are not always co-released. The ability of PAR2 to stimulate selective release of VWF, while causing only minimal release of Pselectin has shown to be based on it's ability to stimulate cAMP and PKA. Although PAR2-AP did not increase global cAMP in HUVEC, PKA inhibition partially attenuated the release of VWF, suggesting that a common downstream pathway is shared between PAR2 and cAMP. Raising intracellular cAMP levels by addition of forskolin did not alter the ability of PAR1-AP to stimulate P-selectin cell surface expression, which suggests that cAMP does not inhibit P-selectin release ( Figure 5D Responses to PAR2-AP differ not only in the time course of VWF secretion compared to PAR1-AP, but also in the reduced ability to release P-selectin, as well as sensitivity to Protein Kinase A inhibition. These findings, taken together, are indicative of differential signaling between the two G-protein coupled PARs. Our findings suggest that the PAR2-AP more closely approximates cAMP raising agents (i.e. forskolin) with respect to its signaling pattern. PAR2-AP has been shown to increase global cAMP levels in melanocytes 36 , however in HUVEC PAR2-AP had no such affect ( Figure 5 ).
Yet, the sensitivity of PAR2-AP stimulation of VWF release to Protein Kinase A inhibition suggests that PAR2-AP may increase local levels of cAMP. Evidence does exist that cAMP signals can be compartmentalized within a cellular domain rather than acting in a uniform and global manner 44, 45 . Expression of HUVEC-specific AKAPs or phosphodiesterases may mediate such local cAMP signaling.
Another alternative explanation for the reduced expression of P-selectin observed with PAR2-AP activation is that PAR2 activation causes preferential release of soluble P-selectin. However, this unlikely as no difference was observed between the PAR agonists in their ability to stimulate release of soluble P-selectin as demonstrated in Figure 4A . Furthermore, to our knowledge, this is the first study to describe the regulated secretion of soluble P-selectin in human endothelial cells. Soluble P-selectin has been reported in the conditioned media of HUVEC 46 , but the ability of agonists to stimulate acute release of soluble P-selectin has not been reported. This may be secondary to the low levels of expression of soluble P-selectin present in HUVEC. Even
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The time course of VWF release is delayed compared to P-selectin which has been attributed to solubilization of VWF strings or ordered multimers of VWF. We have observed the delayed release of VWF compared to P-selectin irrespective of the agonist employed ( Figure 1 ). It has been proposed that VWF multimers bind to P-selectin on the endothelial surface and anchor this highly thrombogenic form of VWF 23 . The delayed release of VWF observed with PAR2-AP and elevations of cAMP compared to thrombin, PAR1-AP, or histamine can not be explained by an increase in VWF multimers binding to the cell membrane because the amount of VWF associated with endothelial surface is an order of magnitude less compared to the amount released (data not shown).
The relatively poor ability of PAR2-AP to stimulate cell-surface expression of Pselectin in HUVEC gives further insight into the role of PAR2 in inflammation.
Depending on the tissue and the vasculature, PAR2 can assume either a protective (anti-inflammatory) or pro-inflammatory role 15, 47 . The administration of PAR2-AP in rats leads to increased leukocyte margination and infiltration in vivo 48, 49 , However, whether PAR2-induced leukocyte recruitment is secondary to leukocyte or endothelial activation is unknown. Indeed, it has been shown that PAR2 is strongly expressed in leukocytes 50 . The present findings together with results of Riewald, et al demonstrating that PAR2
does not lead to increased monocyte chemoattracant Protein-1 expression and secretion 51 suggest that the pro-inflammatory effects of PAR2 activation with respect to The relative poor ability of cAMP agents to cause release of P-selectin also can be viewed in the context of cAMP's known ability to increase barrier function between endothelial cells. Agonists that increase cAMP in the endothelium would not only cause poor release of P-selectin and have a reduced ability to cause leukocyte adhesion, but those leukocytes that did manage to adhere would face an increase in the endothelium barrier that would prevent infiltration. The relative inability of forskolin to cause cell surface expression of P-selectin has pharmacological consequences, for desmospressin is used in the treatment of certain variants of von Willebrand's Disease as a means to achieve hemostasis. One could extrapolate that activation of V2Rs on the endothelium, which couple to adenylyl cyclase and increase cAMP cause a smaller release of P-selectin and subsequent inflammation.
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In conclusion, we clearly demonstrate that VWF and P-selectin, both of which reside in the WPBs, can be differentially regulated by PAR2-AP and forskolin. Clearly, the endothelial secretory response is not binary, and can be influenced by multiple factors, including the nature of the stimulus, receptors involved in downstream signaling, and packaging. Shown starting at the apical surface (panel A-H) and extending to the basal surface imaged every 0.5 μm are z-sections of merged images depicting co-localization of VWF and P-selectin. Histograms in bottom half of panels were generated using the profile feature in the Zeiss LSM image browser and represent the co-localization of P-selectin and VWF when graphed objectively through the red line. Note that when certain granules appear to be composed of entirely P-selectin (green), that when examined objectively, there is underlying VWF (red). Examination of at least 6-8 additional fields yielded similar results. Images were obtained by viewing through a 63X objective. For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
